Triple Threat: Novel Agent Shows Potent T2D Weight Loss

A novel triple agonist targeting the GIP, GLP-1, and glucagon receptors produced unprecedented weight loss in patients with type 2 diabetes after 12 weeks on treatment in a safety study.

Related Keywords

Vienna ,Wien ,Austria ,Prague ,Praha ,Hlavníesto ,Czech Republic ,Stockholm ,Sweden ,Martin Haluzik ,Zvonko Milicevic ,Eli Lilly ,European Association For The Study Of Diabetes ,Charles University ,European Association ,Really Impressive Weight ,Diabetes Mellitus Type 2 ,Iabetes Mellitus Type Ii ,Type 2 Diabetes ,Weight Loss ,Weight Management ,Diabetes Mellitus ,Incretin Hormones ,Incretins ,Glp 1 Receptor Agonists ,Glucagon Like Peptide 1 Receptor Agonists ,Adverse Effects ,Side Effects ,Patient Safety ,Europe ,European ,Hemoglobin A1c ,Hemoglobin A1c Test ,Glycated Hemoglobin ,Glycosylated Hemoglobin ,Ba1c ,A1c ,B1c ,Lycohemoglobin ,Hb ,Hi ,